T4827
群多普利
≥98% (HPLC), white, powder
别名:
(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid, Mavik
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C24H34N2O5
化学文摘社编号:
分子量:
430.54
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white
溶解性
DMSO: ≥20 mg/mL
创始人
Abbott
SMILES字符串
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2C3CCCCC3C[C@H]2C(O)=O
InChI
1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
InChI key
VXFJYXUZANRPDJ-WTNASJBWSA-N
基因信息
human ... ACE(1636)
正在寻找类似产品? 访问 产品对比指南
相关类别
应用
Trandolapril has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on responsiveness of human retinal endothelial cells (HRECs) to vascular endothelial growth factor (VEGF).
生化/生理作用
Studies have reported that trandolapril inhibits atherosclerosis1 and decreases the occurrence of atrial fibrillation2.
Trandolapril is an ACE inhibitor.
Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.
特点和优势
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
制备说明
Trandolapril is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.
警示用语：
Danger
危险声明
危险分类
Repr. 1B
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
O D Pedersen et al.
Circulation, 100(4), 376-380 (1999-07-27)
Studies have suggested that ACE inhibitors have an antiarrhythmic effect on ventricular arrhythmias. Whether they have an effect on atrial fibrillation is unknown. We investigated the effect of ACE inhibition with trandolapril on the incidence of atrial fibrillation in patients
Morten Schou et al.
European journal of clinical investigation, 41(11), 1237-1244 (2011-05-11)
Hyponatremia is a known prognostic factor for mortality in patients with heart failure but has not been extensively studied in patients with myocardial infarction (MI). This study was, therefore, designed to evaluate whether plasma sodium and hyponatremia (< 135 mM)
Alberto F Rubio-Guerra et al.
Therapeutic advances in cardiovascular disease, 5(4), 193-197 (2011-07-09)
Adiponectin is secreted from adipose tissue and exhibits a protective effect against cardiovascular disease; plasma adiponectin concentrations are decreased in type 2 diabetic and in hypertensive patients. The aim of this study was to compare the effect of trandolapril (T)
Ivana Vaněčková et al.
Kidney & blood pressure research, 35(5), 382-392 (2012-04-11)
Our previous studies in rats with ablation nephrectomy have shown similar cardiorenal protective effects of renin-angiotensin system (RAS)-dependent treatment (combination of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker) and RAS-independent treatment (combination of α- and β-adrenoreceptor antagonist and diuretics).
Tobias Gerhard et al.
BMC medical research methodology, 12, 119-119 (2012-08-08)
Due to time-dependent confounding by blood pressure and differential loss to follow-up, it is difficult to estimate the effectiveness of aggressive versus conventional antihypertensive combination therapies in non-randomized comparisons. We utilized data from 22,576 hypertensive coronary artery disease patients, prospectively
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持